We are live on ! Find out more
LFCR icon

Lifecore Biomedical
LFCR

97 hedge funds and large institutions have $279M invested in Lifecore Biomedical in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 33 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 33

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0.74% less ownership

Funds ownership: 87.83% → 87.09% (-0.74%)

3% less capital invested

Capital invested by funds: $287M → $279M (-$8.04M)

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 98 → 97 (-1)

Holders
97
Holders Change
-1
Holders Change %
-1.02%
% of All Funds
1.53%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
11
Increased
34
Reduced
33
Closed
12
Calls
$575K
Puts
–
Net Calls
+$575K
Net Calls Change
+$691K

Top Buyers

Rank Fund Capital Flow
1
WC
Wynnefield Capital
New York
+$4.31M
2
PAIM
Punch & Associates Investment Management
Minnesota
+$3.51M
3
ICM
ISZO Capital Management
New York
+$2.8M
4
PHP
Parkman Healthcare Partners
Connecticut
+$1.28M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$941K

Top Sellers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
-$7.82M
2
William Blair Investment Management
William Blair Investment Management
Illinois
-$4.46M
3
IEFM
IQ EQ Fund Management
Ireland
-$2.83M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.12M
5
BlackRock
BlackRock
New York
-$599K
Name Holding Trade Value Shares
Change 		Change in
Stake
Boston Partners
26
Boston Partners
Massachusetts
$1.34M +$88.2K +7,919 +7%
PHP
27
Parkman Healthcare Partners
Connecticut
$1.33M +$1.28M +115,316 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.27M -$34.4K -3,090 -3%
N
29
Nuveen
North Carolina
$1.24M -$19.8K -1,777 -2%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1.2M -$42.5K -3,814 -4%
Goldman Sachs
31
Goldman Sachs
New York
$1.02M -$108K -9,709 -10%
BCM
32
Bridgeway Capital Management
Texas
$926K -$278K -25,000 -24%
RA
33
Royce & Associates
New York
$876K – – –
GI
34
GAMCO Investors
Connecticut
$869K +$22.3K +2,000 +3%
AA
35
Ancora Advisors
Ohio
$817K – – –
Charles Schwab
36
Charles Schwab
California
$790K +$20.3K +1,826 +3%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$750K +$114K +10,219 +19%
OAM
38
Oppenheimer Asset Management
New York
$708K +$73.9K +6,638 +12%
Invesco
39
Invesco
Georgia
$644K -$18.7K -1,683 -3%
AQR Capital Management
40
AQR Capital Management
Connecticut
$589K -$113K -10,108 -17%
Citadel Advisors
41
Citadel Advisors
Florida
$531K +$511K +45,860 New
Millennium Management
42
Millennium Management
New York
$438K +$298K +26,802 +244%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$422K -$34.7K -3,120 -8%
LCM
44
Lewis Capital Management
California
$414K +$83.1K +7,460 +26%
RP
45
Riverwater Partners
Wisconsin
$378K – – –
Allspring Global Investments
46
Allspring Global Investments
North Carolina
$358K -$439K -39,461 -56%
UBS Group
47
UBS Group
Switzerland
$343K -$196K -17,590 -37%
DT
48
Diversified Trust
Tennessee
$342K – – –
CCB
49
Cutter & Co Brokerage
Missouri
$332K – – –
Wells Fargo
50
Wells Fargo
California
$303K -$310K -27,876 -52%
1
2
3 4 5

LFCR Hedge Fund Activity: Q1 2022 in Review

97 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2022, worth a combined $279M — down 2.8% from $287M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of LFCR and 11 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 34 added.

The largest buyer was Wynnefield Capital, adding an estimated $4.31M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $7.82M sold.

  • 97 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2022, down from 98 in Q4 2021.
  • Funds reported $279M of Lifecore Biomedical stock for Q1 2022, down 2.8% quarter-over-quarter.
  • 11 funds opened new Lifecore Biomedical positions in Q1 2022 and 12 closed out, a net change of -1 holder.
  • The largest Lifecore Biomedical buyer in Q1 2022 was Wynnefield Capital, an estimated $4.31M added.
  • The largest Lifecore Biomedical seller in Q1 2022 was Kennedy Capital Management, an estimated $7.82M sold.

Based on aggregated 13F filings for Q1 2022.